Rheumatoid Arthritis
Conditions
Keywords
survivin, biomarker of pharmacological response, antirheumatic treatment, methotrexate, sulfasalazin, abatacept, tocilizumab, tofacitinib/baricitinib
Brief summary
To validate the utility of survivin as a biomarker of pharmacological response to therapeutic intervention in rheumatoid arthritis patients.
Detailed description
In a prospective observational study the investigators aim to study the ability of modern antirheumatic treatments to suppress levels of survivin in sera. Rheumatoid arthritis patients scheduled to start new pharmacological treatment will be followed for a period of 6 months. No intervention or influence on choice of treatment will be performed, the decision of new/other medication is entirely made by the patient and their rheumatologist. The study entails addition of survivin analyse (1 vial of sera) before and after start of new treatment. Data concerning survivin levels, disease activity and other clinical parameters before and after start of new treatment will also be analysed. The patients will leave sera for survivin analyse at baseline and 3 and 6 months after start of new treatment.
Interventions
DRUGabatacept
Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)
DRUGtocilizumab
IL-6 receptor antagonist
DRUGtofacitinib/baricitinib
JAK inhibitor
DRUGmethotrexate
folate antagonist
DRUGsulfasalazine
Immunomodulatory
Sponsors
Vastra Gotaland Region
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients fulfilling the RA classification criteria according to the ACR/EULAR
Exclusion criteria
* Patients at stable/unchanged anti-rheumatic treatment * Other serious physical or mental illness * Lack of knowledge in Swedish making answering the questionnaires impossible
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Survivin status | 6 months | Patients with a survivin level of over 0.45 ng/ml are considered to be survivin positive. Patients with survivin levels under 0.45 ng/ml are considered to be survivin negative A change from survivin positive to survivin negative (or vice versa) equals conversion of survivin status. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease activity (DAS28) | 6 months | Disease activity, DAS28, is calculated using a specific formula based on: * number of painful joints from 28 joints * number of swollen joints from 28 joints * erythrocyte sedimentation rate (ESR) or C reactive protein (CRP) * patient's global assessment of disease activity on a 100 mm visual analogue scale (VAS) DAS thresholds: DAS28 below 3.2: low disease activity DAS28 over 3.2 and under 5.1: moderate disease activity DAS28 above 5.1: high disease activity DAS28 lower than 2.6: remission |
| Response to treatment | 6 months | The EULAR response criteria classify patients as good, moderate, or non-responders, using the change in DAS28 and the level of DAS28 reached. A patient must show a significant change as well as low disease activity to be classified as a good responder. Good responder: DAS28 scores ≤ 3.2 with reductions in DAS28 \>1.2 Moderate responder: DAS28 scores \> 3.2 with reductions in DAS28 \>1.2 Non-responder: reductions in DAS28 ≤ 0.6 |
Countries
Sweden
Contacts
Primary ContactMaria Bokarewa, MD
Outcome results
None listed